Valuation : Collegium Pharmaceutical, Inc.

Market Cap 861M 743M 697M 636M 1.2B 82.08B 1.2B 8.26B 3.22B 41.51B 3.23B 3.16B 138B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 861M 743M 697M 636M 1.2B 82.08B 1.2B 8.26B 3.22B 41.51B 3.23B 3.16B 138B EV / Sales 2026 *
1.03x
EV / Sales 2027 * 1.04x
Free-Float
77.39%
Yield 2026 *
-
Yield 2027 * -
1 day-4.12%
1 week-7.95%
Current month-28.37%
1 month-28.63%
3 months-24.73%
6 months-39.16%
Current year-45.25%
1 week 25.16
Extreme 25.16
28.25
1 month 25.16
Extreme 25.16
36.64
Current year 25.16
Extreme 25.16
49.31
1 year 25.16
Extreme 25.16
50.79
3 years 20.95
Extreme 20.95
50.79
5 years 14.04
Extreme 14.04
50.79
10 years 7.37
Extreme 7.37
50.79
Manager TitleAgeSince
Chief Executive Officer 51 12/11/2024
Director of Finance/CFO 50 24/05/2021
Chief Tech/Sci/R&D Officer 65 23/03/2022
Director TitleAgeSince
Chairman 69 15/05/2025
Director/Board Member 72 01/02/2014
Director/Board Member 78 01/01/2015
Date Insider Type Main position Quantity % Market Cap.
5/18/26 A Sell

Director

-20 0.0001%
5/15/26 A Fiscal year

Director

21,527 0.0664%
5/14/26 A Free

Director

8,741 0.0270%
Change 5-day change 1-year change 3-year change Capi.($)
-4.12%-7.95%-34.65%+6.20% 861M
-0.13%-5.61%+59.99%+112.16% 1,048B
+0.85%+0.25%+51.61%+61.23% 640B
-1.03%-2.43%+22.79%+74.16% 456B
-1.46%-3.52%+36.60%+38.39% 362B
-0.72%-2.06%+21.34%+37.92% 295B
-1.19%-0.98%+0.79%+12.29% 255B
-1.05%-0.30%+50.16%+68.66% 236B
+0.08%-0.22%-17.16%-53.76% 204B
-2.14%+1.56%+27.88%+89.54% 185B
Average -1.04%-1.05%+21.94%+44.68% 368.25B
Weighted average by Cap. -0.45%-1.92%+37.90%+65.35%

Financials

2026 *2027 *
Net sales 837M 722M 677M 618M 1.16B 79.8B 1.17B 8.03B 3.13B 40.36B 3.14B 3.07B 134B 828M 715M 670M 612M 1.15B 78.97B 1.16B 7.94B 3.1B 39.94B 3.11B 3.04B 133B
Net income - -
Net Debt - -
Logo Collegium Pharmaceutical, Inc.
Collegium Pharmaceutical, Inc. is a diversified biopharmaceutical company. The Company has developed, licensed, and acquired a portfolio of products for use in the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. Its commercial products include Jornay PM (Jornay), Belbuca, Xtampza ER (Xtampza), Nucynta ER and Nucynta IR (Nucynta Products), and Symproic in the United States. Its Jornay is a central nervous system (CNS) stimulant prescription medicine for the treatment of ADHD. The Belbuca is a buccal film that contains buprenorphine for severe and persistent pain. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone. The Xtampza ER is a pain treatment option designed with abuse deterrent properties. Its portfolio also includes AZSTARYS (serdexmethylphenidate and dexmethylphenidate), a central nervous system (CNS) stimulant prescription medicine used for the treatment of ADHD in people six years of age and older.
Employees
423
Date Price Change Volume
28/08/26 $25.35 -4.12% 813,949
27/08/26 $26.44 -3.89% 850,153
26/08/26 $27.51 +0.15% 613,193
25/08/26 $27.47 +0.44% 551,895
24/08/26 $27.35 +0.89% 758,446
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
26.44USD
Average target price
49.60USD
Spread / Average Target
+87.59%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. COLL Stock